Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
Cheapism on MSN

Drugmakers will raise prices on hundreds of medications in 2026 — here are some of them

Check out some of the medications affected by drugmakers raising prices on life-saving medications this year, as well as some ...
The Daily Overview on MSN

9 pharma giants strike deals with Trump to cut drug prices

President Donald Trump has locked in a sweeping set of pricing agreements with nine of the world's biggest drugmakers, promising to pull some of the most expensive medicines on the U.S. market closer ...
Yahoo Finance

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
Reuters

Pfizer says patient dies after receiving hemophilia drug in trial

Dec 23 (Reuters) - A patient who was being treated with Pfizer's (PFE.N), opens new tab hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the ...
Yahoo Finance

Pfizer Stock Is Down -- Patient Death in Hemophilia Study Raises Safety Concerns

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) shares slid about 1% Tuesday morning after reports that a patient died while receiving the company's hemophilia drug Hympavzi, highlighting ...
Yahoo

Pfizer says patient dies after receiving hemophilia drug in trial

FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Dec 23 (Reuters) - A ...
Seeking Alpha

Pfizer reports patient death in hemophilia trial for Hympavzi

Pfizer (PFE) on Tuesday announced that a patient who was taking part in a long-term extension trial for its hemophilia therapy Hympavzi (marstacimab) died after serious adverse events. The patient ...
Bloomberg L.P.

Patient Dies After Taking Pfizer’s Drug for Blood Disorder

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders. The death occurred on Dec. 14 after the patient ...
Benzinga.com

Pfizer Reports Patient Death In Marstacimab Hemophilia Extension Study

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...
FiercePharma

Pfizer confirms patient death in Hympavzi hemophilia extension study

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...